Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- ImClone: Non-Justifiable Scientific Downgrades Refuted
- The recent findings of clinical trials on the safety and efficacy of ImClone Systems' IMCL Erbitux in regard to advanced colo-rectal cancer refute the frivolous claim/downgrade by Friedman, Billings Ramsey & Co. analyst Jim Reddoch. The above mentioned analysts, who have absolutely no medical training in evaluating clinical trials, cited...
- External links 2008-08-06
- Genentech?s New ADC Platform Has Much Potential, but Is Yet to Be Tested on Humans
- Ohad Hammer submits: On June 18th, Seattle Genetics SGEN announced it had received a milestone payment from Genentech DNA after the latter filed an IND Investigational New Drug application for an antibody-drug conjugate [ADC] powered by Seattle Genetics’ technology. Intriguingly, there was no additional data about the new agent, nor...
- External links 2008-08-06
- Be Selective with Medical Device Companies
- Zacks.com submits: With earnings season beginning to wind down in the medical devices and supplies industry, we figured it would be a good time to check in with Zacks senior analyst Tom Park. We were looking to see if there are any attractive buys among his coverage....
- External links 2008-08-06
- What's Going On at Roche Palo Alto?
- Derek Lowe submits: I've just been told by a reliable source that something big is up with the Roche (RHHBY.PK)-Palo Alto site. I don't know if this is part of their bid for Genentech DNA or what, but the word "closing" has been mentioned. I hate to pass...
- External links 2008-08-06
- Icahn Racks Up Gains in ImClone, Motorola, and Amylin
- Lon Juricic submits: Activist investor Carl Icahn had a nice day yesterday. Here's why:Bristol-Myers BMY sent Mr. Icahn a letter presenting a $60 per share offer for ImClone Systems IMCL. Icahn is the Chairman of ImClone, and owns 11,669,544 shares of the biotech company. With shares of ImClone...
- External links 2008-08-01
- FDA Delivers Another Blow to Amgen?s Anemic Drug Sales
- The Simplified Investor submits: Amgen (NYSE:AMGN) made its reputation as one of the premier firms in the biotechnology industry with its blockbuster anemia drugs, Aranesp and Epogen. Worldwide sales of anemia drugs made up around half of Amgen’s $14.8B revenue in 2007 and an even larger percentage of its...
- External links 2008-08-01
- Wallstrip: Micrus Endovascular Corp. (MEND)
- Micrus Endovascular Corp. is in the business of prolonging life, and overseas markets appear to be just what the doctor ordered.
- Videos 2008-07-14
- Myriad's Not Doing Much
- Trader Mark submits: We restarted a position in Myriad Genetics MYGN as a long term "growth at good value" play about 6 weeks ago, despite a horrid technical condition on the chart. Since then the stock has just sort of hung around and done nothing, trading in a very...
- External links 2009-11-06
- FDA Calendar Update: Cell Therapeutics
- Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 285 entries as of 7/29/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA....
- External links 2009-07-29
- Nephros Awaits Two Pending FDA Marketing Clearances
- Mike Havrilla submits: Nephros (NEPH.OB) is a medical device company which originally developed HDF products for ESRD patients and has since expanded its core business to include water filtration, including FDA marketing clearance for the company's DSU filters in early July. A summary of the company's products includes the following:...
- External links 2009-07-29
- Biotech Volatility: Antigenics, BioDelivery Sciences
- VFC submits: Antigenics Shares of Antigenics AGEN soared over thirty percent on Tuesday before retreating to close the day at $2.99. Volume was over three times the daily average and no significant news was released. Since there has not been a news release during the run up period,...
- External links 2009-07-29
- Rigel Pharma: The Importance of Knowing Your Stock
- Stone Fox Capital submits: Last Thursday night, Rigel Pharma RIGL released disappointing results on its TASKi3 Phase 2b study on Rheumatoid Arthritis (RA). The results showed that the placebo worked basically as well as the R788 pill. Now here is where you need to understand the stock and what was...
- External links 2009-07-29
- Life Technologies Corporation Q2 2009 Earnings Call Transcript
- Life Technologies Corporation LIFE Q2 2009 Earnings Call Transcript July 28, 2009 4:00 pm ET
- External links 2009-07-28
- Lexicon Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
- Lexicon Pharmaceuticals, Inc. LXRX Q2 2009 Earnings Call Transcript July 28, 2009 11:00 am ET
- External links 2009-07-28
- Waters Corporation Q2 2009 Earnings Call Transcript
- Waters Corporation WAT Q2 2009 Earnings Call July 28, 2009 8:30 am ET
- External links 2009-07-28
- Bemis Co. Inc. Q2 2009 Earnings Call Transcript
- Bemis Co. Inc. BMS Q2 2009 Earnings Call July 28, 2009 10:00 am ET
- External links 2009-07-28
- QLT Inc. Q2 2009 Earnings Call Transcript
- QLT Inc. QLTI Q2 2009 Earnings Call July 28, 2009 8:30 am ET
- External links 2009-07-28
- Amgen 2Q Earnings Beat; Raises Guidance, Announces Denosumab Deal
- Mike Havrilla submits: Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS) of $1.29 for 2Q09, an increase of 13% compared to $1.14 for the 2Q08 see conference call transcript here. Adjusted net income increased 6% to $1.3 billion during 2Q09 versus $1.2 billion during 2Q08. Total revenue declined by 1%...
- External links 2009-07-27
- Amgen, Inc. Q2 2009 Earnings Call Transcript
- Amgen, Inc. AMGN Q2 2009 Earnings Call July 27, 2009 5:00 pm ET
- External links 2009-07-27
- Access Pharma Regains MuGard Rights in North America
- Mike Havrilla submits: Access Pharma (ACCP.OB) announced on 7/29/09 that the Company's previously announced licensing agreement with Milestone Biosciences, LLC for the North American rights to commercialize and market MuGard has been terminated. In addition, Frank Jacobucci (formerly President & CEO of Milestone Biosciences), has joined Access as a consultant...
- External links 2009-07-29
- << Previous
- page 1 of 43
- Next >>
Content Types
Refining Tags
- Healthcare (246 results)
- VFC's Stock House (74 results)
- Mike Havrilla (69 results)
- Derek Lowe (64 results)
- Zacks.com (48 results)
- Seeking Alpha (48 results)
- ChinaBio Today (38 results)
- Pfizer Inc. (37 results)
- Genentech Inc. (35 results)
- china (34 results)
- Eli Lilly & Co. (30 results)
- Mike Huckman (30 results)
- Trader Mark (29 results)
- Finance (24 results)
- Dendreon Corp. (23 results)
- Antigenics Inc. (23 results)
- Amylin Pharmaceuticals Inc. (21 results)
- BioDelivery Sciences International Inc. (20 results)
- M. E. Garza (19 results)
- Novartis AG (19 results)
- Amgen Inc. (18 results)
- Genzyme Corp. (17 results)
- Bristol-Myers Squibb Co. (17 results)
- Celgene Corp. (16 results)
- US Market (16 results)
- Myriad Genetics Inc. (16 results)
- Merck & Co. Inc. (16 results)
- Sequenom Inc. (15 results)
- ImClone Systems Inc. (15 results)
- Spectrum Pharmaceuticals Inc. (14 results)
- Biogen Idec Inc. (14 results)
- GlaxoSmithKline Plc. (14 results)
- EP Vantage (14 results)
- Emergent Biosolutions (13 results)
- theflyonthewall.com (13 results)
- Gilead Sciences Inc. (12 results)
- Greenbackd (12 results)
- Investment (12 results)
- Wyeth (11 results)
- Biotechnology (11 results)
- Vanda Pharmaceuticals Inc. (11 results)
- Financial Accounting (11 results)
- CEL-SCI Corp. (10 results)
- Michael Catalin Vlaicu (10 results)
- Cell Therapeutics Inc. (9 results)
- Agilent Technologies Inc. (8 results)
- Prohost Biotech (8 results)
- Johnson & Johnson (8 results)
- Geron Corp. (8 results)
- Illumina Inc. (8 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
